"These findings indicate that frailty is a strong independent predictor for adverse in-patient outcomes in hospitalized CML patients . . . Frailty not only poses greater risk for in-hospital death in ...
Researchers recently calculated the estimated savings over a 30-year period with regard to CML patients who attempt to get off their TKI therapy. In what they referred to as a 'conservative' estimate, ...
According to new research, 80% of patients with previously untreated or relapsed/refractory advanced-phase chronic myeloid leukemia (CML) -- including both accelerated or myeloid blast phases of the ...
DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H1 2016" report to their offering. This ...
A lower number of CD26+ LSCs at diagnosis correlates with optimal molecular response in CML patients at 3, 12, and 24 months.
Chronic myeloid leukemia (CML) is a type of blood cancer. CML is Philadelphia chromosome-positive (Ph+) when pieces of chromosomes 9 and 22 break off and swap places. This creates a new abnormal ...
The company announced that data from the ongoing CARDINAL trial of TERN-701 in participants with previously treated chronic myeloid leukemia (CML) will be presented at the 67th American Society of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback